Dilevalol

Summary

Dilevalol (CHEMBL27193) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 328.4 Da · C19H24N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL27193
Name	Dilevalol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	134044
ChEBI	CHEBI:94471
Molecular formula	C19H24N2O3
Molecular weight	328.4
InChIKey	SGUAFYQXFOLMHL-ACJLOTCBSA-N

SMILES: C[C@H](CCC1=CC=CC=C1)NC[C@@H](C2=CC(=C(C=C2)O)C(=O)N)O

IUPAC name: 2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-4-phenylbutan-2-yl]amino]ethyl]benzamide

ChEBI definition: A 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide that has 1R,2R-configuration.

Also known as: (r,r)-labetalol, Dilevalol, Labetalol (r,r)-form, DILEVALOL

Parent form; salt/anhydrous children: CHEMBL1204165

Patent coverage: 684 distinct patent families (2,804 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: 5-hydroxytryptamine receptor 1A.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P19327	6.53	Ki	295.1	nM	CHEMBL_ACT_854217

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).